EP0966479A4 - Polyprolyl agissant en tant qu'inhibiteur de la cyclophiline - Google Patents

Polyprolyl agissant en tant qu'inhibiteur de la cyclophiline

Info

Publication number
EP0966479A4
EP0966479A4 EP97953231A EP97953231A EP0966479A4 EP 0966479 A4 EP0966479 A4 EP 0966479A4 EP 97953231 A EP97953231 A EP 97953231A EP 97953231 A EP97953231 A EP 97953231A EP 0966479 A4 EP0966479 A4 EP 0966479A4
Authority
EP
European Patent Office
Prior art keywords
polyprolyl
cyclophiline
inhibitor
acting
polyprolyl acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97953231A
Other languages
German (de)
English (en)
Other versions
EP0966479A1 (fr
Inventor
Gregory S Hamilton
Ling Wei
Joseph P Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Guilford Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc filed Critical Guilford Pharmaceuticals Inc
Publication of EP0966479A1 publication Critical patent/EP0966479A1/fr
Publication of EP0966479A4 publication Critical patent/EP0966479A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP97953231A 1996-12-09 1997-12-08 Polyprolyl agissant en tant qu'inhibiteur de la cyclophiline Withdrawn EP0966479A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76190296A 1996-12-09 1996-12-09
US761902 1996-12-09
PCT/US1997/023102 WO1998025950A1 (fr) 1996-12-09 1997-12-08 Polyprolyl agissant en tant qu'inhibiteur de la cyclophiline

Publications (2)

Publication Number Publication Date
EP0966479A1 EP0966479A1 (fr) 1999-12-29
EP0966479A4 true EP0966479A4 (fr) 2004-12-08

Family

ID=25063558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97953231A Withdrawn EP0966479A4 (fr) 1996-12-09 1997-12-08 Polyprolyl agissant en tant qu'inhibiteur de la cyclophiline

Country Status (8)

Country Link
EP (1) EP0966479A4 (fr)
JP (1) JP2001505920A (fr)
AR (1) AR010744A1 (fr)
AU (1) AU5702698A (fr)
CA (1) CA2263828A1 (fr)
PA (1) PA8442401A1 (fr)
WO (1) WO1998025950A1 (fr)
ZA (1) ZA9710989B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140676A0 (en) 1998-07-17 2002-02-10 Agouron Pharma Compounds, compositions, and methods for stimulating neuronal growth and elongation
US6544976B1 (en) 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
RU2241709C2 (ru) 1999-07-09 2004-12-10 Орто-Макнейл Фармасьютикал, Инк. Производные азотсодержащих гетероциклических соединений и способ лечения расстройств, характеризующихся поражением нейронов
WO2001004090A2 (fr) 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Tetrahydro-isoquinolines et tetrahydrothienopyridines neurotrophiques, compositions et procedes associes
HRP20020737A2 (en) * 2000-02-11 2005-10-31 Vertex Pharmaceuticals Incorporated Piperazine and piperidine derivatives for treatment or prevention of nruronal damage
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US10501741B2 (en) 2014-06-25 2019-12-10 Cold Spring Harbor Laboratory Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (EMT) in cancer cells
ES2928207T5 (en) 2018-04-10 2026-02-16 Sanofi Aventis Deutschland Lixisenatide synthesis with capping

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006450A1 (fr) * 1992-09-17 1994-03-31 Universtiy Of Florida Apport stimule par le cerveau de peptides neuroactifs par metabolisme sequentiel
WO1997018828A1 (fr) * 1995-11-20 1997-05-29 Guilford Pharmaceuticals Inc. Inhibiteurs d'activite de cyclophiline rotamase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
JP2782142B2 (ja) * 1992-07-23 1998-07-30 カルピス株式会社 アンジオテンシン変換酵素阻害剤及びその製造法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006450A1 (fr) * 1992-09-17 1994-03-31 Universtiy Of Florida Apport stimule par le cerveau de peptides neuroactifs par metabolisme sequentiel
WO1997018828A1 (fr) * 1995-11-20 1997-05-29 Guilford Pharmaceuticals Inc. Inhibiteurs d'activite de cyclophiline rotamase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9825950A1 *
STEINER ET AL: "Neurotrophic actions of non-immunosuppressive analogs of immunosuppressive drugs FK506, rapamycin and cyclosporin A", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 4, April 1997 (1997-04-01), pages 421 - 428, XP002125244, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
EP0966479A1 (fr) 1999-12-29
CA2263828A1 (fr) 1998-06-18
PA8442401A1 (es) 2000-05-24
AU5702698A (en) 1998-07-03
JP2001505920A (ja) 2001-05-08
ZA9710989B (en) 1999-05-25
AR010744A1 (es) 2000-07-12
WO1998025950A1 (fr) 1998-06-18

Similar Documents

Publication Publication Date Title
ID22992A (id) Turunan-turunan 9-deokso-9a-aza-9a-homoeritromisin a tersubstitusi-4"
DE59605821D1 (de) l/4-SCALLABSORBER
FR2735198B1 (fr) Piece d'accastillage de type manille-cosse
BR9605267A (pt) Inibidor de angiogenese
EP0945459A4 (fr) Derives de l'erythromicine a
SV1996000004A (es) 2-(2-n-alcoxifenil)-purin-6-onas 9 sustituidas
BR9611723A (pt) Bifenil éter-oxazolinas
NO961404D0 (no) 4-indolylpiperazinyl-derivater
NO960353L (no) 4-aminobenzoylguanidinderivater
BR9709521A (pt) "3-Cianoaril-pirazóis"
NO960392D0 (no) 4-merkaptobenzoylguanidinderivater
FR2735986B3 (fr) Prolongateur d'haltere
FR2768628B1 (fr) Composition prophylactique adaptee a la prevention de l'enterite paratuberculeuse
UA10890A (uk) Мікроіh'єктор
FI953860A0 (fi) Yhdistelmäpalkki
UA25945C2 (uk) Гірка hастояhка "святкова"
SE9504432D0 (sv) Ma 3005
SE9501893D0 (sv) Grepp 1
ITCS970006V0 (it) "1 m"
KR970043321U (ko) 브레이커 굴러의 피스톤
BR9606017A (pt) "Enrotrilan"
UA908S (uk) Тапочки чоловічі
UA1384S (uk) Етикетка "нарзан"
UA1383S (uk) Етикетка "нарзан"
KR970005813U (ko) 슈트홀의 응급보수기

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990412

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20041025

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/28 B

Ipc: 7A 61P 25/16 B

Ipc: 7A 61P 25/02 B

Ipc: 7A 61K 38/08 B

Ipc: 7A 61K 38/07 B

Ipc: 7C 07K 5/10 B

Ipc: 7C 07K 7/06 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051126